Observational Study on Comorbidities and Infections in People with Multiple Sclerosis (PwMS)
The study found that PwMS have a higher prevalence of chronic diseases and infections compared to matched controls. Key findings showed that comorbidity burden was influenced by factors such as male gender and older age. Higher comorbidity and having infections were linked to increased 5-year mortality rates in PwMS.
- Tags
- #Other
- Most relevant to
- —
Why it matters
Understanding the comorbidity and infection burden in PwMS may improve patient care and treatment approaches by highlighting the need for monitoring and addressing these issues.
What this does not prove
The study only includes data from 2019, limiting the analysis to a single year and not considering longer-term trends in infections and comorbidity burden.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Yes
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-14
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Other
Original sources
- Primary evidenceComorbidities and infectious episodes in multiple sclerosis patients within general practices in the Netherlands. ↗DOI: 10.1016/j.msard.2026.107927
Supporting passages (9)
study designMETHODS: This retrospective case-control study was conducted the Dutch Nivel Primary Care Database from the year 2019, assessing chronic comorbidities and infections in PwMS versus matched controls.
subjectsBACKGROUND: People with multiple sclerosis (PwMS) are at heightened risk of comorbidities and infections, due to the disease's debilitating nature and side effects of disease-modifying therapies (DMT).
controlledversus matched controls.
research categoriesPrevention, early detection and treatment of comorbidities may ameliorate prognosis of MS and the presence of comorbidities should be part of individualized DMT MS patient care.
publication date2026-09-14
comparatormatched controls
primary endpointCCI scores of 1 and ≥2 were associated with significantly increased 5-year mortality (aHR 1.86 and 3.30, respectively), as was having at least one infectious episode in 2019 (aHR 1.68).
findingsComorbidity burden was higher in male PwMS, older age, prolonged disease duration, and lower socio-economic status (SES).
limitationsTitle: Comorbidities and infectious episodes in multiple sclerosis patients within general practices in the Netherlands.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.